Company Overview of BioDiem Ltd.
BioDiem Limited, a biotechnology company, discovers, develops, and commercializes pharmaceutical and biomedical research for the treatment and prevention of cancers and infectious diseases. It offers Nasovac-S, a seasonal influenza vaccine based on live attenuated influenza virus technology. The company also engages in the expansion and development of vaccine technologies, including live attenuated influenza virus technology for use in seasonal and pandemic influenza vaccines; and antimicrobial BDM-I for the treatment of infectious diseases. In addition, it provides SAVINE antigen technology for the treatment of tuberculosis, Epstein Barr virus, HIV, and other diseases; flavivirus vaccine te...
100 Albert Road
Melbourne, VIC 3205
Key Executives for BioDiem Ltd.
Chief Executive Officer and Executive Director
Chief Financial Officer and Company Secretary
Compensation as of Fiscal Year 2014.
BioDiem Ltd. Key Developments
BioDiem Ltd. Auditor Raises 'Going Concern' Doubt
Sep 30 14
BioDiem Ltd. filed its Annual on Sep 30, 2014 for the period ending Jun 30, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
BioDiem Ltd., Annual General Meeting, Oct 23, 2014
Sep 30 14
BioDiem Ltd., Annual General Meeting, Oct 23, 2014., at 15:00 AUS Eastern Standard Time. Location: Grant Thornton, Wills Room, The Rialto, Level 30, 525 Collins Street. Agenda: To consider annual report for the financial year ending 30 June 2014; to consider re-election of Director, Hugh Matheson Morgan; and to consider re-election of Director Larisa Georgievna Rudenko.
BioDiem Ltd. Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014
Sep 15 14
BioDiem Ltd. reported audited consolidated earnings results for the year ended June 30, 2014. For the year, the company reported revenue of $113,939 against $101,615 a year ago. Loss before income tax expense was $1,018,349 against $2,316,160 a year ago. Loss after income tax expense for the year attributable to the owners of the company was $1,018,349 against $2,316,160 a year ago. Net cash used in operating activities was $1,101,070 against $1,984,638 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|